Baricitinib, an oral JAK inhibitor, in combination with topical corticosteroids in adult patients with moderate to severe atopic dermatitis
Baricitinib ( Olumiant ) has met the primary endpoint in BREEZE-AD7, the third pivotal phase 3 trial in the BREEZE-AD program to be completed in 2019.
BREEZE-AD7, an investigational study evaluatin ...
read article